| |
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Today’s Big NewsJan 8, 2025 |
|
The U.S. Department of Veterans Affairs (VA) is at the forefront of healthcare innovation, developing cutting-edge technologies to improve the lives of veterans . Now, your business can leverage these advancements. Download today to learn more! 
|
|
| By James Waldron Galapagos has never been a company to sit still for long, but—even by its own standards—the decision to split in two while waving goodbye to 40% of its employees and a long-standing Gilead partnership is a bold move. |
|
|
|
By Conor Hale Johnson & Johnson MedTech announced that it has paused U.S. procedures and sales of its recently approved Varipulse pulsed field ablation system, following reports of four patient strokes. |
By Fraiser Kansteiner CDMO National Resilience plans to lay off roughly 120 workers at its Research Triangle Park facility in Durham, North Carolina, according to a notice filed with the state this week. The cuts will affect staffers Resilience inherited in its buyout of the facility from gene therapy specialist bluebird bio in 2021. |
By Gabrielle Masson Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s stock price up by about 200%. |
|
As the market for complex biologics continues to grow, effective capacity planning becomes more challenging. The entry of the 5,000L single-use bioreactor (SUB) is providing an important bridge between small-scale and large-scale production, offering more flexibility than ever before to respond to fluctuations in demand quickly and efficiently. Access this report to learn more. 
|
|
By Conor Hale The Dublin-based company also announced that the FDA has handed down a breakthrough designation to its Norm system, which includes a minimally invasive sensor that sits within the body’s largest vein to help monitor for unsafe buildups in a patient’s internal fluid levels. |
By Conor Hale Set to close within the first half of the year, the deal could see Boston Scientific compete in the future against systems from Abbott, Philips and J&J, among others. |
By Kevin Dunleavy The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis. The ruling will affect GSK’s Arexvy and Pfizer’s Abrysvo. |
By Darren Incorvaia Roche's Chugai Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. The Japanese unit is tapping Zurich-based Araris Biotech to develop new antibody-drug conjugates. |
By Andrea Park Armgo Pharma is making a fresh start this new year, as the Boston-based biotech announced Tuesday that it will henceforth be known as RyCarma Therapeutics. |
By Zoey Becker Novo's new insulin Awiqli and obesity prospect CagriSema are each expected to rake in billions by 2030, according to Clarivate Analytics’ Drugs to Watch in 2025 report. Lilly's Ebglyss is also in line for a major haul. |
By Andrea Park Following the departure of its global managing director of health and life sciences for a new role at Takeda last fall, FleishmanHillard has now tapped Mary Kosinski to take the reins of its largest sector. |
By Gabrielle Masson Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics. |
By Nick Paul Taylor Swoop has taken control of more than 60 patient communities by acquiring MyHealthTeam, positioning the Real Chemistry spinout to offer new communication options to its pharma clients. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download now to take your cell and gene therapy techniques to new heights. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
